Mein Warenkorb

HGF

HGF Molekülinformation

Englischer NameHepatocyte growth factorAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel7Target-AliasEC 3.4.21.7,Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor),EC 3.4.21,HGF,Hepatopoietin-A,Scatter factor,Hepatocyte Growth Factor (Hepapoietin A,Scatter Factor),Fibroblast-Derived Tumor Cytotoxic Factor,Lung Fibroblast-Derived Mitogen,SF,Deafness, Autosomal Recessive 39,Hepatopoietin A,DFNB39,F-TCF,HGFB,Hepatocyte Growth Factor,HPTA
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameHepatocyte growth factor
Target-AliasEC 3.4.21.7,Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor),EC 3.4.21,HGF,Hepatopoietin-A,Scatter factor,Hepatocyte Growth Factor (Hepapoietin A,Scatter Factor),Fibroblast-Derived Tumor Cytotoxic Factor,Lung Fibroblast-Derived Mitogen,SF,Deafness, Autosomal Recessive 39,Hepatopoietin A,DFNB39,F-TCF,HGFB,Hepatocyte Growth Factor,HPTA
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphaseApproved

HGF Produktliste

  • Attribut

    Protein (4)Kits (1)

  • Produktbibliothek

    Online (5)

  • Spezies

    Human (5)

  • Etikett

    His Tag (1)Fc Tag (1)- (1)Tag Free (2)

  • Marker

    Unconjugated (4)- (1)

HGF Molekülhintergrund

Hepatocyte growth factor (HGF) is a paracrine cellular growth, motility and morphogenic factor. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. In addition, HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast.

HGF Molekülalias

HGF,HPTA,SF

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
FosgonimetonNDX-1017; ATH-1017; ATH 1017Phase 3 ClinicalM3 BiotechnologyAlzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease
Details
RGL-2102RGL-2102; RGL2102Phase 3 ClinicalShanghai Regenelead Therapies Co LtdDiabetic Foot; Ischemia; Ulcer; Wound Infection
Details
FiclatuzumabAV-299; SCH-900105Phase 3 ClinicalAveoCarcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
UmikibartYYB-101; NOV-1105; CLM-101Phase 2 ClinicalYooYoung Pharmaceutical Co LtdColorectal Neoplasms; Solid tumours
Details
ATH-1020ATH-1020Phase 1 ClinicalAthira Pharma IncNerve Degeneration
Details
ATH-1105ATH-1105Phase 1 ClinicalAthira Pharma IncAmyotrophic Lateral Sclerosis; Frontotemporal Dementia
Details
Microbiome-optimized autologous stem cell therapy (Biotech Holdings)ClinicalBiotech HoldingsPeripheral Vascular Diseases
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Beperminogene perplasmidAMG-0001-01; AMG-0001; DS-992; TREAT-HGFApprovedAnges Mg, Osaka UniversityCollategeneJapanPeripheral Arterial Disease; IschemiaAnges Inc, null2019-03-01Arterial Occlusive Diseases; Atherosclerosis; Foot Ulcer; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases; Ulcer; Vascular Diseases
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns